CAMBRIDGE, Mass., July 28, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented results from a Phase 1 study of M118, its rationally engineered anticoagulant, demonstrating the absence of a significant drug-drug interaction between M118 and aspirin (ASA) and clopidogrel. This data is being presented at the IXth World Conference on Clinical Pharmacology and Therapeutics Meeting in a poster titled "Lack of Drug-Drug Interactions with M118, a Novel, Rationally Engineered Low Molecular Weight Heparin, When Co-Administered with Multiple Doses of Aspirin and Clopidogrel."
